Su Hsien Lim, MD

Assistant Professor of Medicine (Medical Oncology)

DownloadHi-Res Photo

Are You a Patient?

View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

View Doctor Profile

Contact Info

suhsien.lim@yale.edu

About

Titles

Assistant Professor of Medicine (Medical Oncology)

Appointments

Medical Oncology and Hematology
Assistant Professor
Primary

All Institutions
Internal Medicine
Medical Oncology
Medical Oncology and Hematology
Subset Medical Oncology Faculty
Yale Cancer Center
Yale Medicine
Yale New Haven Health System

Education & Training

Fellowship: Memorial Sloan Kettering Cancer Center (2008)

Fellowship: Memorial Sloan Kettering Cancer Center: New York, NY (2008)

Residency: Bellevue Hospital (2004)

Residency: Memorial Sloan Kettering Cancer Center: New York, NY (2004)

Residency: New York University - Bellevue Hospital Center (2004)

MD: New York University School of Medicine (2001)

MD: New York University School of Medicine, New York, NY (2001)

Research

Publications

2007

Doxorubicin and concurrent radiotherapy for anaplastic thyroid cancer: We need to do better
Lim S, Lee N, Fury M, Ghossein R, Shaha A, Wolden S, Pfister D. Doxorubicin and concurrent radiotherapy for anaplastic thyroid cancer: We need to do better. Journal Of Clinical Oncology 2007, 25: 16506-16506. DOI: 10.1200/jco.2007.25.18_suppl.16506.
Peer-Reviewed Original Research
Concepts

Clinical Trials

Current Trials

Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
HIC ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028
Recruiting Participants
Lymphoma
A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)
HIC ID2000030190RoleSub InvestigatorPrimary Completion Date06/02/2026
Recruiting Participants
Lymphoma
Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
HIC ID2000028918RoleSub InvestigatorPrimary Completion Date01/30/2026
Recruiting Participants
Myeloma
Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
HIC ID2000029969RoleSub InvestigatorPrimary Completion Date12/31/2027
Recruiting Participants
Myeloma
A Randomized Phase II Trial Of Circulating Tumor DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
HIC ID2000029678RoleSub InvestigatorPrimary Completion Date12/15/2023
Recruiting Participants
Breast Cancer

See All Current Clinical Trials

Clinical Care

Overview

Medical Oncology; Hematology & Oncology

Fact Sheets

Myeloproliferative Neoplasms
Learn More on Yale Medicine
Thrombocytopenia
Learn More on Yale Medicine
Myelodysplastic/Myeloproliferative Neoplasms
Learn More on Yale Medicine
Hormonal Therapy for Cancer
Learn More on Yale Medicine

See All Fact Sheets On Yale Medicine

Yale Medicine News

See All News On Yale Medicine

View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

View Doctor Profile

News

February 23, 2024
Department of Internal Medicine Promotions and Appointments (February 2024)
Read moreabout Department of Internal Medicine Promotions and Appointments (February 2024)

Get In Touch

Contacts

suhsien.lim@yale.edu

Appointment Number

203.453.9192

Clinic Fax Number

203.453.0875

Locations

Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
See Patient Care Locations

Su Hsien Lim, MD

Are You a Patient?

Contact Info

About

Titles

Appointments

Medical Oncology and Hematology

Other Departments & Organizations

Education & Training

Research

Publications

2007

Doxorubicin and concurrent radiotherapy for anaplastic thyroid cancer: We need to do better

Clinical Trials

Current Trials

Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma

A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)

Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

A Randomized Phase II Trial Of Circulating Tumor DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer

Clinical Care

Overview

Clinical Specialties

Fact Sheets

Myeloproliferative Neoplasms

Thrombocytopenia

Myelodysplastic/Myeloproliferative Neoplasms

Hormonal Therapy for Cancer

Yale Medicine News

Are You Iron Deficient? 8 Things Women Should Know

Are You Getting Enough Vitamin B12? What You Need to Know

Are You a Patient?

News

News

Department of Internal Medicine Promotions and Appointments (February 2024)

Get In Touch

Contacts

Locations

Patient Care Locations